Występowanie i funkcja peptydu glukagonopodobnego 1 (GLP-1) w przewodzie pokarmowym ssaków oraz zastosowanie kliniczne jego analogów

• Autorzy: Gorska A. , Arciszewski M.B.

Warianty tytułu

EN

Distribution and function of glucagon-like peptide 1 (GLP-1) in the digestive tract of mammals and the clinical use of its analogues

• Języki publikacji: PL

Abstrakty

EN

Recently, interest in glucagon-like peptide-1 (GLP-1) and other peptides derived from preproglucagon has increased significantly. GLP-1 is a 30-amino acid peptide hormone produced in L-type enteroendocrine cells as a response to food intake. GLP-1 is rapidly metabolized and inactivated by the dipeptidyl peptidase IV enzyme before the hormone leaves the intestine, which increases the likelihood that GLP-1 action is transmitted through sensory neurons in the intestine and liver through the GLP-1 receptor. The main actions of GLP-1 are to stimulate insulin secretion (i.e. act as incretin hormone) and inhibit glucagon secretion, thus contributing to the reduction of postprandial glucose spikes. GLP-1 also inhibits motility and gastrointestinal secretion, and therefore acts as part of the „small bowel brake” mechanism. GLP-1 also appears to be a physiological regulator of appetite and food intake. Because of these effects, GLP-1 or GLP-1 receptor agonists are now increasingly used to treat type 2 diabetes. Reduced GLP-1 secretion may contribute to the development of obesity, and excessive secretion may be responsible for postprandial reactive hypoglycemia. The use of GLP-1 agonists opens up new possibilities for the treatment of type 2 diabetes and other metabolic diseases. In the last two decades, many interesting studies covering both the physiological and pathophysiological role of GLP-1 have been published, and our understanding of GLP-1 has broadened significantly. In this review article, we have tried to describe our current understanding of how GLP-1 works as both a peripheral hormone and as a central neurotransmitter in health and disease. We focused on its biological effects on the body and the potential clinical application in relation to current research.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2020
• Tom: 76
• Numer: 07
• Opis fizyczny: s.382-388,bibliogr.

Twórcy

autor

Gorska A.

• Katedra Anatomii i Histologii Zwierząt, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul. Akademicka 12, 20-033 Lublin

autor

Arciszewski M.B.

• Katedra Anatomii i Histologii Zwierząt, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul. Akademicka 12, 20-033 Lublin

Bibliografia

• 1. Alvarez E., Martinez M. D., Roncero I., Chowen J. A., Garcia-Cuartero B., Gispert J. D., Sanz C., Vazquez P., Maldonado A., de Caceres J., Desco M., Pozo M. A., Blazquez E.: The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 2005, 92, 798-806.
• 2. Andreasen J. J., Orskov C., Holst J. J.: Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy. Digestion 1994, 55, 221-228.
• 3. Anini Y., Brubaker P. L.: Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 2003, 144, 3244-3250.
• 4. Bell G. I., Sanchez-Pescador R., Laybourn P. J., Najarian R. C.: Exon duplication and divergence in the human preproglucagon gene. Nature 1983, 304, 368-371.
• 5. Bell G. I., Santerre R. F., Mullenbach G. T.: Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983, 302, 716-718.
• 6. Blonde L., Klein E. J., Han J., Zhang B., Mac S. M., Poon T. H., Taylor K. L., Trautmann M. E., Kim D. D., Kendall D. M.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006, 8, 436-447.
• 7. Bonner-Weir S.: Beta-cell turnover: its assessment and implications. Diabetes 2001, 50 Suppl 1, 20-24.
• 8. Bose A. K., Mocanu M. M., Carr R. D., Brand C. L., Yellon D. M.: Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54, 146-151.
• 9. Buffa R., Capella C., Fontana P., Usellini L., Solcia E.: Types of endocrine cells in the human colon and rectum. Cell Tissue Res. 1978, 192, 227-240.
• 10. Bullock B. P., Heller R. S., Habener J. F.: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137, 2968-2978.
• 11. Buteau J., El-Assaad W., Rhodes C. J., Rosenberg L., Joly E., Prentki M.: Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47, 806-815.
• 12. Butler A. E., Janson J., Bonner-Weir S., Ritzel R., Rizza R. A., Butler P. C.: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52, 102-110.
• 13. Cheang J. Y., Moyle P. M.: Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes. ChemMedChem. 2018, 13, 662-671.
• 14. Creutzfeldt W.: Entero-insular axis and diabetes mellitus. Horm. Metab. Res. Suppl. 1992, 26, 13-18.
• 15. Creutzfeldt W. O., Kleine N., Willms B., Orskov C., Holst J. J., Nauck M. A.: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care 1996, 19, 580-586.
• 16. Dakin C. L., Gunn I., Small C. J., Edwards C. M., Hay D. L., Smith D. M., Ghatei M. A., Bloom S. R.: Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001, 142, 4244-4250.
• 17. De Heer J., Hoy M., Holst J. J.: GLP-1, but not GIP, inhibits glucagon secretion via somatostatin in the perfused rat pancreas (Abstract). Diabetologia 2005, 48 Suppl 1, A64.
• 18. Deacon C. F., Johnsen A. H., Holst J. J.: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80, 952-957.
• 19. Drucker D. J., Asa S.: Glucagon gene expression in vertebrate brain. J. Biol. Chem. 1988, 263, 13475-13478.
• 20. During M. J., Cao L., Zuzga D. S., Francis J. S., Fitzsimons H. L., Jiao X., Bland R. J., Klugmann M., Banks W. A., Drucker D. J., Haile C. N.: Glucagonlike peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003, 9, 1173-1179.
• 21. Egan J. M., Bulotta A., Hui H., Perfetti R.: GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab. Res. Rev. 2003, 19, 115-123.
• 22. Eissele R., Goke R., Willemer S., Harthus H. P., Vermeer H., Arnold R., Goke B.: Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 1992, 22, 283-291.
• 23. Elliott R. M., Morgan L. M., Tredger J. A., Deacon S., Wright J., Marks V.: Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J. Endocrinol. 1993, 138, 159-166.
• 24. Eng J., Kleinman W. A., Singh L., Singh G., Raufman J. P.: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992, 267, 7402-7405.
• 25. Fehmann H. C., Goke R., Goke B.: Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 1995, 16, 390-410.
• 26. Gault V. A., O’Harte F. P., Harriott P., Mooney M. H., Green B. D., Flatt P. R.: Effects of the novel (Pro3)GIP antagonist and exendin (9-39) amide on GIPand GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 2003, 46, 222-230.
• 27. Gebhard B., Holst J. J., Biegelmayer C., Miholic J.: Postprandial GLP-1, norepinephrine, reactive hypoglycemia in dumping syndrome. Dig. Dis. Sci. 2001, 46, 1915-1923.
• 28. Goke R., Larsen P. J., Mikkelsen J. D., Sheikh S. P.: Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 1995, 7, 2294-2300.
• 29. Grimelius L., Capella C., Buffa R., Polak J. M., Pearse A. G., Solcia E.: Cytochemical and ultrastructural differentiation of enteroglucagon and pancreatic-type glucagon cells of the gastrointestinal tract. Virchows Arch. B Cell Pathol. 1976, 20, 217-228.
• 30. Groger G., Unger A., Holst J. J., Goebell H., Layer P.: Ileal carbohydrates inhibit cholinergically stimulated exocrine pancreatic secretion in humans. Int. J. Pancreatol. 1997, 22, 23-29.
• 31. Gromada J., Holst J. J., Rorsman P.: Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch. 1998, 435, 583-594.
• 32. Guidone C., Manco M., Valera-Mora E., Iaconelli A., Gniuli D., Mari A., Nanni G., Castagneto M., Calvani M., Mingrone G.: Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006, 55, 2025-2031.
• 33. Hansen L., Deacon C. F., Orskov C., Holst J. J.: Glucagon-like peptide-1- (7-36) amide is transformed to glucagon-like peptide-1- (9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140, 5356-5363.
• 34. Hansen L., Hartmann B., Bisgaard T., Mineo H., Jørgensen P. N., Holst J. J.: Somatostatin restrains the secretion of glucagon-like peptide-1 and 2 from isolated perfused porcine ileum. Am. J. Physiol. Endocrinol. Metab. 2000, 278, 1010-1018.
• 35. Hansen L., Holst J. J.: The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno-ileal loop? Regul. Pept. 2002, 110, 39-45.
• 36. Hansen L., Lampert S., Mineo H., Holst J. J.: Neural regulation of glucagon-like peptide-1 secretion in pigs. Am. J. Physiol. Endocrinol. Metab. 2004, 287, 939-947.
• 37. Heinrich G., Gros P., Habener J. F.: Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J. Biol. Chem. 1984, 259, 14082-14087.
• 38. Herrmann-Rinke C., Voge A., Hess M., Goke B.: Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J. Endocrinol. 1995, 147, 25-31.
• 39. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., Sugimoto Y., Miyazaki S., Tsujimoto G.: Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 2005, 11, 90-94.
• 40. Hölscher C.: Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 2014, 221, 31-41.
• 41. Holst J. J.: Enteroglucagon. Annu. Rev. Physiol. 1997, 59, 257-271.
• 42. Holst J. J., Gromada J.: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am. J. Physiol. Endocrinol. Metab. 2004, 287, 199-206.
• 43. Holst J. J., Orskov C.: Incretin hormones – an update. Scand. J. Clin. Lab. Invest. Suppl. 2001, 75-85.
• 44. Hutch C. R., Sandoval D.: The Role of GLP-1 in the Metabolic Success of Bariatric Surgery. Endocrinology 2017, 158, 4139-4151.
• 45. Jin S. L., Han V. K., Simmons J. G., Towle A. C., Lauder J. M., Lund P. K.: Distribution of glucagonlike peptide I (GLP-I), glucagon, glicentin in the rat brain: an immunocytochemical study. J. Comp. Neurol. 1988, 271, 519-532.
• 46. Kanoski S. E., Hayes M. R., Skibicka K. P.: GLP-1 and weight loss: unraveling the diverse neural circuitry. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016, 310, 885-895.
• 47. Kauth T., Metz J.: Immunohistochemical localization of glucagon-like peptide 1. Use of poly- and monoclonal antibodies. Histochemistry 1987, 86, 509-515.
• 48. Kjems L. L., Holst J. J., Volund A., Madsbad S.: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52, 380-386.
• 49. Knudsen J. B., Holst J. J., Asnaes S., Johansen A.: Identification of cells with pancreatic-type and gut-type glucagon immunoreactivity in the human colon. Acta Pathol. Microbiol. Scand. 1975, 83, 741-743.
• 50. Larsen P. J., Tang-Christensen M., Holst J. J., Orskov C.: Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997, 77, 257-270.
• 51. Le Roux C. W., Aylwin S. J., Batterham R. L., Borg C. M., Coyle F., Prasad V., Shurey S., Ghatei M. A., Patel A. G., Bloom S. R.: Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, improve metabolic parameters. Ann. Surg. 2006, 243, 108-114.
• 52. Mayo K. E., Miller L. J., Bataille D., Dalle S., Goke B., Thorens B., Drucker D. J.: International Union of Pharmacology. XXXV. The Glucagon Receptor Family. Pharmacol. Rev. 2003, 55, 167-194.
• 53. McIntyre N., Holdsworth C. D., Turner D. S.: Intestinal factors in the control of insulin secretion. J. Clin. Endocrinol. Metab. 1965, 25, 1317-1324.
• 54. Miholic J., Orskov C., Holst J. J., Kotzerke J., Meyer H. J.: Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), reactive hypoglycemia after total gastrectomy. Dig. Dis. Sci. 1991, 36, 1361-1370.
• 55. Mortensen K., Christensen L. L., Holst J. J., Orskov C.: GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 2003, 114, 189-196.
• 56. Murlin J. R., Clough H. D., Gibbs C. B. F., Stokes A. M.: Aqueous extracts of the pancreas. I. Influence on the carbohydrate metabolism of depancreatized animals. J. Biol. Chem. 1923, 56, 253-296.
• 57. Naslund E., Barkeling B., King N., Gutniak M., Blundell J. E., Holst J. J., Rossner S., Hellstrom P. M.: Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int. J. Obes. Relat. Metab. Disord. 1999, 23, 304-311.
• 58. Nauck M., Schmidt W. E., Ebert R., Strietzel J., Cantor P., Hoffmann G., Creutzfeldt W.: Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, cholecystokinin-8. J. Clin. Endocrinol. Metab. 1989, 69, 654-662.
• 59. Nauck M., Stockmann F., Ebert R., Creutzfeldt W.: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29, 46-52.
• 60. Nauck M. A., Heimesaat M. M., Orskov C., Holst J. J., Ebert R., Creutzfeldt W.: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993, 91, 301-307.
• 61. Nauck M. A., Homberger E., Siegel E. G.: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 1986, 63, 492-498.
• 62. Nauck M. A., Kleine N., Orskov C., Holst J. J., Willms B., Creutzfeldt W.: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36, 741-744.
• 63. Nauck M. A., Niedereichholz U., Ettler R., Holst J. J., Orskov C., Ritzel R., Schmiegel W. H.: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. Endocrinol. Metab. 1997, 273, 981-988.
• 64. Nian M., Gu J., Irwin D. M., Drucker D. J.: Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282, 173-183.
• 65. Orci L., Bordi C., Unger R. H., Perrelet A.: Glucagon- and glicentin-producing cells. Glucagon 1983, 66/1, 57-79.
• 66. Orci L., Pictet R., Forssmann W. G., Renold A. E., Rouiller C.: Structural evidence for glucagon producing cells in the intestinal mucosa of the rat. Diabetologia 1968, 4, 56-67.
• 67. Orskov C., Holst J. J., Nielsen O. V.: Effect of truncated glucagon-like peptide-1 [proglucagon- (78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123, 2009-2013.
• 68. Orskov C., Holst J. J., Poulsen S. S., Kirkegaard P.: Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987, 30, 874-881.
• 69. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J. J.: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43, 535-539.
• 70. Orskov C., Wettergren A., Holst J. J.: Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 1996, 31, 665-670.
• 71. Patti M. E., McMahon G., Mun E. C., Bitton A., Holst J. J., Goldsmith J., Hanto D. W., Callery M., Arky R., Nose V., Bonner-Weir S., Goldfine A. B.: Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005, 48, 2236-2240.
• 72. Perley M., Kipnis D. M.: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest. 1967, 46, 1954-1962.
• 73. Perry T. A., Greig N. H.: A new Alzheimer’s disease interventive strategy: GLP-1. Curr. Drug Targets. 2004, 5, 565-571.
• 74. Rask E., Olsson T., Soderberg S., Johnson O., Seckl J., Holst J. J., Ahren B.: Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001, 24, 1640-1645.
• 75. Read N., French S., Cunningham K.: The role of the gut in regulation food intake in man. Nutr. Rev. 1994, 52, 1-10.
• 76. Rocca A. S., Brubaker P. L.: Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999, 140, 1687-1694.
• 77. Schick R. R., Walde T., Zimmermann J. P., Schusdziarra V., Classen M.: Glucagon-like peptide 1: a novel brain peptide involved in feeding regulation. Obesity in Europe 1993, edited by Ditschuneit H., Gries F. A., Hauner H., Schusdziarra V., Wechsler J. G. Libbey 1994, 363-367.
• 78. Schjoldager B. T., Mortensen P. E., Christiansen J., Orskov C., Holst J. J.: GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 1989, 34, 703-708.
• 79. Shah P., Vella A., Basu A., Basu R., Schwenk W. F., Rizza R. A.: Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2000, 85, 4053-4059.
• 80. Sutherland E. W., De Duve C.: Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J. Biol. Chem. 1948, 175, 663-674.
• 81. Tang-Christensen M., Vrang N., Larsen P. J.: Glucagon-like peptide 1 (7-36) amide’s central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998, 47, 530-537.
• 82. Thorens B., Widmann C.: Signal transduction and desensitization of the glucagon-like peptide-1 receptor. Acta Physiol. Scand. 1996, 157, 317-319.
• 83. Toft-Nielsen M., Madsbad S., Holst J. J.: Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 1998, 41, 1180-1186.
• 84. Toft-Nielsen M. B., Madsbad S., Holst J. J.: Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J. Clin. Endocrinol. Metab. 2001, 86, 3853-3860.
• 85. Unger R. H., Ketterer H., Eisentraut A. M.: Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism 1966, 15, 865-867.
• 86. Verdich C., Flint A., Gutzwiller J. P., Naslund E., Beglinger C., Hellstrom P. M., Long S. J., Morgan L. M., Holst J. J., Astrup A.: A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 2001, 86, 4382-4389.
• 87. Verdich C., Toubro S., Buemann B., Lysgard M. J., Juul H. J., Astrup A.: The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Int. J. Obes. Relat. Metab. Disord. 2001, 25, 1206-1214.
• 88. Vila Petroff M. G., Egan J. M., Wang X., Sollott S. J.: Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ. Res. 2001, 89, 445-452.
• 89. Vilsboll T., Holst J. J.: Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004, 47, 357-366.
• 90. Vilsboll T., Knop F. K., Krarup T., Johansen A., Madsbad S., Larsen S., Hansen T., Pedersen O., Holst J. J.: The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J. Clin. Endocrinol. Metab. 2003, 88, 4897-4903.
• 91. Vilsboll T., Krarup T., Deacon C. F., Madsbad S., Holst J. J.: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50, 609-613.
• 92. Vilsboll T., Krarup T., Sonne J., Madsbad S., Volund A., Juul A. G., Holst J. J.: Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2003, 88, 2706-2713.
• 93. Wei Y., Mojsov S.: Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995, 358, 219-224.
• 94. Wettergren A., Maina P., Boesby S., Holst J. J.: Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man. Scand. J. Gastroenterol. 1997, 32, 552-555.
• 95. Wettergren A., Schjoldager B., Mortensen P. E., Myhre J., Christiansen J., Holst J. J.: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 1993, 38, 665-673.
• 96. Willms B., Werner J., Holst J. J., Orskov C., Creutzfeldt W., Nauck M. A.: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)- (7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 1996, 81, 327-332.
• 97. Wroge J., Williams N. T.: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. Ann. Pharmacother. 2016, 50, 1041-1050.
• 98. Yamamoto H., Lee C. E., Marcus J. N., Williams T. D., Overton J. M., Lopez M. E., Hollenberg A. N., Baggio L., Saper C. B., Drucker D. J., Elmquist J. K.: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 2002, 110, 43-52.
• 99. Zander M., Madsbad S., Madsen J. L., Holst J. J.: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359, 824-830.

Identyfikatory

DOI

10.21521/mw.6374